The HD Tirsema 44 Pen is a lyophilised research preparation marketed in South Africa that combines tirzepatide (a GIP/GLP-1 dual agonist) and semaglutide (a selective GLP-1 receptor agonist) at a declared total peptide content of 44 mg per pen, intended for in vitro comparative work on incretin receptor signalling.
No peer-reviewed study published between 2023 and 2026 has co-administered tirzepatide and semaglutide in the same experimental system. The mechanistic rationale for this combined format is extrapolated from dual-agonist pharmacology rather than direct combination data. Both parent molecules are scheduled S4 prescription medicines under SAHPRA (South African Health Products Regulatory Authority) when supplied as registered human products (Mounjaro, Ozempic/Wegovy). Unregistered research-grade material falls under the broader Medicines and Related Substances Act framework.
Key Takeaways
- HD Tirsema 44 Pen combines tirzepatide and semaglutide in a single lyophilised preparation for in vitro receptor-signalling research
- Tirzepatide engages both GIP and GLP-1 receptors; semaglutide engages GLP-1 only, creating a competitive-binding confound at GLP-1R that requires single-agent control arms
- No published in vitro study between 2023 and 2026 has directly co-administered both peptides, making this an open mechanistic question
- The preparation is unregistered in South Africa and permitted only for laboratory research, not human or veterinary use
- A four-arm design (vehicle, semaglutide alone, tirzepatide alone, combined) isolates additive versus redundant signalling
What Is HD Tirsema 44 Pen?
HD Tirsema 44 Pen is a lyophilised combined research peptide preparation containing tirzepatide and semaglutide at a declared total peptide mass of 44 mg per pen. It is supplied in South Africa for in vitro and laboratory investigation of incretin receptor signalling. The "HD" prefix denotes the high-dose format relative to lower-mass single-agent pens in the same vendor catalogue. It is not intended for human or veterinary administration.
The two active components target overlapping but non-identical receptor systems. Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Semaglutide is a selective GLP-1 receptor agonist with no meaningful affinity for the GIP receptor.
Combining them in a single preparation produces redundant GLP-1R occupancy alongside isolated GIPR stimulation from the tirzepatide fraction. That signalling profile is examined in detail below.
The 44 mg total mass figure comes from vendor product specification rather than a SAHPRA-registered assay. The individual tirzepatide:semaglutide ratio is not disclosed on publicly accessible product documentation as of 2026. Researchers comparing the combined format against single-agent controls such as the Body Pharm Tirzepatide 30 Pen should request a batch-specific certificate of analysis (COA). Related combined-format stock keeping units (SKUs) are catalogued under Tirsema research preparations.
Tirzepatide vs Semaglutide: Receptor Mechanisms
Tirzepatide engages both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), while semaglutide engages GLP-1R only. Combining the two in a single preparation produces simultaneous GLP-1R occupancy by two distinct agonists alongside isolated GIPR stimulation from the tirzepatide fraction. That receptor-saturation profile is the central confound any in vitro design using the Tirsema research preparations must account for.
Incretin biology in brief
The incretin effect refers to the greater insulin response to oral versus intravenous glucose. This response is attributed primarily to GIP secreted from intestinal K-cells and GLP-1 from L-cells. Both peptides act on class B1 G-protein-coupled receptors that couple to Gαs, raising intracellular cyclic adenosine monophosphate (cAMP), which potentiates glucose-dependent insulin secretion from pancreatic β-cells.
GLP-1R activation additionally suppresses glucagon release from α-cells and slows gastric emptying through vagal afferent signalling. GIPR signalling in adipocytes modulates lipid handling and, depending on glycaemic state, can either augment or attenuate glucagon secretion.
Why the two molecules signal differently
Semaglutide is a long-acting GLP-1R agonist with no meaningful GIPR affinity. It produces canonical Gαs-cAMP and β-arrestin recruitment at GLP-1R.
Tirzepatide, characterised by Coskun and colleagues in Cell Metabolism (2022), is a 39-amino-acid synthetic peptide. It behaves as a full agonist at GIPR and as a biased agonist at GLP-1R, favouring Gαs coupling over β-arrestin recruitment relative to native GLP-1. That bias reduces GLP-1R internalisation kinetics and sustains surface receptor availability during prolonged exposure, which is why tirzepatide shows sustained signalling in cell culture systems. No mechanism papers published between 2023 and 2025 alter this characterisation.
The co-occupancy confound at GLP-1R
When tirzepatide and semaglutide are co-incubated with a cell line expressing GLP-1R, the two ligands compete for the same orthosteric binding pocket. Downstream cAMP and phosphorylated extracellular signal-regulated kinase (pERK) readouts cannot be cleanly attributed to either agent without orthogonal controls.
Typical controls include a tirzepatide-only arm at matched GLP-1R-equivalent concentration and a semaglutide-only arm such as the format catalogued alongside the Body Pharm Tirzepatide 30 Pen. GIPR-specific signalling is attributable to tirzepatide alone in this system, since semaglutide contributes no GIPR occupancy. Studies designed without that decomposition conflate additive GLP-1R signalling with genuine dual-receptor synergy.
Why Combine Tirzepatide and Semaglutide in One Preparation?
A combined tirzepatide-plus-semaglutide preparation lets researchers interrogate maximal incretin receptor engagement, GIPR/GLP-1R cross-talk, and pharmacodynamic interaction kinetics in a single assay run. The alternative is inferring those effects by stitching together separate single-agent datasets. The trade-off is a competitive-binding confound at GLP-1R that single-agent arms do not present.
Maximal incretin receptor engagement baseline
Running a co-incubation arm establishes the upper ceiling of cAMP, pERK, or insulin secretion achievable when both GIPR and GLP-1R are simultaneously occupied at saturating concentration. That ceiling becomes the reference against which tirzepatide-only and semaglutide-only arms are normalised. Without a co-stimulation baseline, a single-agent dose-response curve cannot distinguish between true receptor saturation and ligand-specific efficacy ceilings imposed by biased agonism at GLP-1R.
Pairing the HD Tirsema 44 pen with a Body Pharm Tirzepatide 30 Pen and a single-agent semaglutide pen lets one assay matrix cover all three conditions from the same batch of cells.
Receptor cross-talk and signal integration
GIPR and GLP-1R are both Gαs-coupled but recruit β-arrestin with different kinetics. They are co-expressed on pancreatic β-cells, adipocytes, and select central nervous system (CNS) neurons. Co-stimulation experiments ask whether downstream integration is additive, sub-additive, or supra-additive at the level of cAMP accumulation, CREB phosphorylation, or insulin granule exocytosis.
No published in vitro study between 2023 and 2026 has directly co-administered tirzepatide and semaglutide in the same well. The Tirsema research preparations format is purpose-built to address that gap.
Pharmacodynamic interaction modelling
Isobologram and Loewe additivity analyses require co-exposure at multiple fixed-ratio concentrations to construct interaction surfaces. A pre-formulated 44 mg combined pen shortens preparation time and reduces pipetting-error variance compared with reconstituting two separate vials per dose point.
The receptor-saturation confound
Combined preparations do not simply add effects at GLP-1R. Semaglutide and tirzepatide compete for the same orthosteric pocket. The apparent GLP-1R signal in a co-incubation reflects whichever ligand wins occupancy at the local concentration, not the sum of two independent inputs.
The SURPASS-CVOT programme (initiated 2020, ongoing 2023 readouts) was designed as a head-to-head comparison of tirzepatide versus semaglutide rather than a combination trial. The additive-versus-redundant question at GLP-1R remains unresolved in humans. No registered Phase 2 or Phase 3 trial has co-administered the two agents as of 2026. In vitro preparations remain the only empirical route to address this question.
HD Tirsema 44 Pen: Format and Dosing Specification
The HD Tirsema 44 Pen is a lyophilised research preparation supplying 44 mg total combined tirzepatide and semaglutide peptide mass in a pre-assembled pen-format cartridge, intended for reconstitution in bacteriostatic water immediately before in vitro use. Vendor listings do not disclose the exact tirzepatide-to-semaglutide molar ratio within the 44 mg total. Any ratio assumption must be confirmed against the batch COA at receipt.
The pen delivery format matters for high-throughput work. Reconstituting a single 44 mg cartridge once, then aliquoting into 96-well or 384-well plate stock solutions, removes the inter-vial variance that arises when two separate single-agent vials are reconstituted in parallel. For isobologram designs requiring 8–12 fixed-ratio dose points across triplicate plates, the larger peptide reservoir reduces the number of reconstitution events per experimental run.
Format comparison across locally available pens
| Product | Total peptide mass | Receptor target(s) | Format |
|---|---|---|---|
| HD Tirsema 44 Pen | 44 mg (combined) | GIP-R + GLP-1R (dual ligand mix) | Lyophilised pen |
| Body Pharm Tirzepatide 30 Pen | 30 mg | GIP-R + GLP-1R (single dual-agonist) | Lyophilised pen |
| Body Pharm Tirzepatide 60 Pen | 60 mg | GIP-R + GLP-1R (single dual-agonist) | Lyophilised pen |
| Body Pharm Semaglutide 6 Pen | 6 mg | GLP-1R | Lyophilised pen |
The 44 mg combined format sits between the 30 mg and 60 mg single-agent tirzepatide pens on raw mass. It is the only locally available preparation containing both peptides in a single cartridge within the Tirsema research preparations range.
Storage follows the convention for analogous incretin research peptides: refrigerated at 2–8 °C, protected from light. The post-reconstitution working solution is kept at 2–8 °C and used within the window specified on the supplied COA.
Research Protocol Context: Where Tirsema Fits
A four-arm in vitro design is the cleanest way to position HD Tirsema 44 within a comparative incretin study:
- Vehicle control
- Semaglutide single-agent
- Tirzepatide single-agent
- Combined HD Tirsema preparation
The combined arm quantifies any signal above and beyond the single-agent maxima at GLP-1R and GIP-R, that is the empirical question separating additive from redundant signalling at saturating doses.
In the protocols I run, matched molar concentrations across all four arms are non-negotiable. The 44 mg figure is a combined mass and the vendor-supplied ratio of tirzepatide to semaglutide is not independently validated in the peer-reviewed literature. Molar equivalents must be calculated from the batch-specific COA before any dosing series is built.
Tirzepatide (~4,813 Da) and semaglutide (~4,114 Da) differ enough in molar mass that mass-matched dosing would skew receptor occupancy estimates. Convert to nanomolar (nM) equivalents per component, then build the dose-response on those values rather than on combined mass.
Suggested four-arm framework
Arm 1 uses bacteriostatic water vehicle at matched osmolarity.
Arm 2 uses semaglutide reconstituted from a single-agent pen such as the Body Pharm Semaglutide 6 Pen, dosed at 0.1–100 nM.
Arm 3 uses tirzepatide from the Body Pharm Tirzepatide 30 Pen, matched on GLP-1R molar occupancy to Arm 2.
Arm 4 uses HD Tirsema 44, dosed so that the tirzepatide and semaglutide components individually equal the Arm 2 and Arm 3 concentrations.
This is a suggested framework, not a validated protocol. No peer-reviewed in vitro study published between 2023 and 2026 has directly co-administered the two peptides. Each laboratory should clear the design through its institutional biosafety and ethics structures and document the rationale against SAHPRA's unregistered-medicines framework.
For groups planning forward-looking work, Retatrutide (the triple GIP/GLP-1/glucagon agonist with Phase 3 readouts expected through 2025–2026) is the logical next comparator once dual-agonist baselines are locked. See the Tirsema research preparations range for related stock formats.
Regulatory Status in South Africa (2026)
HD Tirsema 44 Pen is an unregistered research preparation in South Africa and may be used only for in vitro laboratory work, not human or veterinary administration. Its supply and handling fall under the Medicines and Related Substances Act 101 of 1965 (as amended by Act 72 of 2008 and subsequent amendments), administered by SAHPRA.
Tirzepatide is registered with SAHPRA as the human medicine Mounjaro, classified Schedule 4 (prescription-only) for type 2 diabetes. Semaglutide carries the same Schedule 4 status in its registered forms (Ozempic, Wegovy).
The HD Tirsema 44 research preparation is a distinct product. It has no SAHPRA registration number and is not approved for human use. SAHPRA has not issued a peptide-specific "research chemical" exemption as of 2026. Unregistered GLP-1/GIP analogues are handled under the Act's general unregistered-medicines provisions and the section 21 authorisation pathway for any human-subject application.
Research-use procurement sits in a narrow lane: in vitro and ex vivo work conducted within a registered laboratory, documented against institutional biosafety, ethics, and waste-disposal standard operating procedures (SOPs). Verify your institution's specific position on unregistered peptide imports before ordering. Retain the COA and import documentation with the batch record. The broader Tirsema research preparations catalogue, alongside single-agent comparators such as the Body Pharm Tirzepatide 30 Pen, is sold on the same basis.
Disclaimer: HD Tirsema 44 Pen is supplied for laboratory research only. It is not a registered medicine, not intended for human or animal administration, and not for diagnostic or therapeutic use. Purchasers confirm compliance with the Medicines and Related Substances Act 101 of 1965 and their institutional regulations.
Ordering HD Tirsema 44 Pen in South Africa
Orders are placed through the JCSG.org secure checkout, with ZAR pricing displayed on the product page and shipping calculated at the cart stage. Current pricing is not reproduced here because vendor figures shift with batch availability and exchange-rate adjustments. Check current pricing on the product page rather than relying on cached numbers.
Dispatch is by tracked courier within South Africa, packaged discreetly without external product branding. The 44 mg lyophilised cartridge is shipped at ambient temperature, which is acceptable for dry peptide in transit. On arrival, transfer immediately to 2–8 °C refrigeration, or to −20 °C for extended pre-reconstitution storage, in line with standard incretin peptide handling. Inspect the seal and the accompanying COA before logging the batch into your inventory system.
For comparative procurement, the Tirsema research preparations category lists adjacent formats. The Body Pharm Tirzepatide 30 Pen is the single-agent reference SKU for tirzepatide-only arms.
View current availability and pricing on the HD Tirsema 44 Pen product page.
Frequently Asked Questions
Is HD Tirsema 44 Pen safe for human use?
No. HD Tirsema 44 Pen is supplied strictly for in vitro and preclinical laboratory investigation and is not a SAHPRA-registered medicinal product. Both tirzepatide and semaglutide are classified as Schedule 4 prescription medicines in South Africa when supplied as registered human products (Mounjaro, Ozempic, Wegovy). Unregistered combination preparations have no approved human application.
What is the mechanistic difference between tirzepatide and semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is a selective GLP-1 receptor agonist. Tirzepatide additionally engages biased signalling at GLP-1R, altering the kinetics of receptor internalisation and signal persistence. That difference is the pharmacological reason a combined preparation is of interest for receptor-occupancy and downstream cAMP comparison studies.
How should HD Tirsema 44 Pen be stored?
Store the lyophilised cartridge refrigerated at 2–8 °C, protected from light, with reconstitution in bacteriostatic water immediately before first use. −20 °C is acceptable for extended pre-reconstitution storage. Confirm the exact window against the batch COA supplied with your shipment.
Can HD Tirsema be run alongside single-agent pens in the same study?
Yes. A multi-arm design is the recommended use case. Pairing HD Tirsema with the Body Pharm Tirzepatide 30 Pen and a semaglutide-only arm isolates additive versus redundant signalling contributions. The single-agent arms provide the baseline against which the combined preparation's output can be decomposed. The Tirsema research preparations category lists adjacent dose formats for dose-response curves.
Is this product available for delivery across South Africa?
Yes. Dispatch is by tracked courier nationwide in discreet packaging, with the dry cartridge shipped at ambient temperature and transferred to refrigeration on arrival.
Next Steps
If your laboratory is planning in vitro incretin receptor work, begin by confirming your institution's approval pathway for unregistered peptide research under SAHPRA's framework. Request a batch-specific COA from the vendor before ordering, and calculate molar equivalents for tirzepatide and semaglutide separately rather than dosing by combined mass. A four-arm design pairing HD Tirsema 44 with single-agent controls will isolate whether the combined preparation produces additive, redundant, or synergistic signalling at saturating receptor occupancy. Contact the Tirsema research preparations product page to check current availability and place an order.
